Inducible nitric oxide synthase (iNOS) helps drive numerous inflammatory disorders, but its inhibition has not had therapeutic success. Now Seimetz et al. (2011) make a case for inhibiting iNOS in an effort to treat one of the world's leading causes of death-chronic obstructive pulmonary disease.
In 1992, the gas nitric oxide (NO) was crowned ''molecule of the year'' by Science magazine. In the same year, the high-output isoform of NO synthase (which generates orders of magnitude more NO than other isoforms) was cloned and named ''iNOS'' for its inducibility by inflammatory and immunologic stimuli and independence of elevated intracellular calcium (Xie et al., 1992) . iNOS went on to enjoy success in two arenas: linguistics and pathophysiology. Linguistically, iNOS called forth iPSCs from cell biologists and iNKT cells and iTregs from immunologists, as well as an array of ''iProducts'' from the technology sector. In pathophysiology, the enzyme was found to play prominent roles in many settings, from endotoxic shock (MacMicking et al., 1995) to host defense (Nathan and Shiloh, 2000) , and now the literature includes nearly 25,000 articles dealing with iNOS.
However, in the arena of therapeutics, iNOS did not catch fire. The proinflammatory roles of iNOS (Bogdan, 2001 ) made it a choice target. Disappointingly, though, no marked clinical benefits have emerged from blocking iNOS in septic shock, asthma, or other conditions, despite the development of progressively more selective inhibitors that spare the other NOS isoforms, nNOS (NOS1) and eNOS (NOS3). Now, 20 years after iNOS was first purified, new findings suggest that its therapeutic inhibition deserves a fresh look. Among these findings, Seimetz et al. report in this issue of Cell the remarkable observation that disrupting or inhibiting iNOS prevented or reversed important manifestations of chronic obstructive pulmonary disease (COPD) in mice (Seimetz et al., 2011) .
The World Health Organization warns that COPD may become the third leading cause of death by 2030. In 2005, more than 80 million people suffered from the disease, and 3 million succumbed. The chief cause of COPD is inhalation of smoke from tobacco and cooking fires and of air pollutants from automotive and industrial activities. Prominent forms of the disease include chronic bronchitis (i.e., inflammation of the larger airways) and emphysema (i.e., destruction of the alveoli, or air sacs). Some patients also have pulmonary hypertension (i.e., high pressure in the pulmonary artery), which can lead to heart failure. COPD is incurable except by lung transplantation, and there is no therapy to halt its progression. The inadequate treatment options and the numerous interventions under consideration (Barnes and Stockley, 2005) point to gaps in our understanding of COPD's pathophysiologic mechanisms. Now research from the Weissmann group (Seimetz et al., 2011) brightens this gloomy picture. When the authors exposed mice to tobacco smoke for up to 8 months, the lungs of the mice resembled those of patients with advanced COPD, including loss of alveoli, elastic fibers, and small blood vessels. The lungs of the mice also displayed thickening of the remaining vessels, increased iNOS in smooth muscle, decreased eNOS, and increased protein nitration-additional features found in patients with COPD.
Use of a mouse model allowed three major insights into the pathogenesis of COPD. First, smoke exposure caused emphysema and pulmonary hypertension in wild-type mice and in mice lacking eNOS, but not in mice lacking iNOS. Moreover, when the authors administered an iNOS inhibitor after 8 months of smoke exposure, the treatment reversed the lung damage within 3 months. Second, the smoke's effects on pulmonary vasculature and pulmonary arterial pressure preceded those on airways and were not attributable to hypoxia. Third, bone marrow transplantation experiments demonstrated that emphysema depended on iNOS expression in radiation-resistant, nonhematopoietic cells, but pulmonary hypertension required expression of iNOS in cells derived from the bone marrow. These findings raise new questions about the chain of causality in COPD. They also commend iNOS inhibition as an experimental therapy.
Renewed interest in therapeutic inhibition of iNOS is emerging in other settings as well (Figure 1) . Although the first biologic effect that could be attributed in retrospect to an action of iNOS was killing of tumor cells (Hibbs et al., 1987) , iNOS can also promote tumor growth. Two recent examples are noteworthy. Human glioma stem cells depend on iNOS for their proliferation and tumorigenicity, and administration of an iNOS inhibitor that crosses the blood-brain barrier retarded the growth of human glioma grafts in the brains of mice (Eyler et al., 2011) . iNOS is also expressed in inflammatory cells that infiltrate mouse and human tumors. iNOS produces NO from arginine. When arginase is present, arginine is limiting, and iNOS begins to generate superoxide in addition to NO. These two radicals can react to form peroxynitrite, which can nitrate proteins. A recent study in mice showed that iNOS-dependent nitration of the chemokine CCL2 forestalled the entry of cytolytic T cells into the tumor (Molon et al., 2011) . Inhibiting peroxynitrite generation by iNOS markedly improved immunologic control of the tumors (Molon et al., 2011) .
Should clinical investigators rush to test iNOS inhibitors in patients with emphysema, especially those with pulmonary hypertension? This depends on the meaning of ''rush.'' Highly specific iNOS inhibitors with suitable pharmaceutical properties are at hand. However, their experimental use in emphysema should be initiated only when key criteria are met. Subjects need to be appropriately phenotyped and stratified, so that patients with similar types of emphysema at similar stages of severity are equally represented in the experimental and control groups. Appropriate biomarkers need to be selected to allow proof of mechanism. Appropriate endpoints should be included such that proof of concept need not depend solely on rates of mortality. Finally, mechanisms should be in place to monitor safety. It will be particularly important to exclude patients with subclinical infections, such as tuberculosis, which iNOS may help control (Nathan and Shiloh, 2000) . iNOS can inhibit proliferation of T cells (Bogdan, 2001 ). Thus, it will also be important to watch for the possible expansion of the oligoclonal populations of T cells whose presence in the lungs of some patients with COPD suggests reactivity against a limited set of antigens, as seen in autoimmune diseases (Cosio et al., 2009) .
Activation of iNOS in diverse contexts can lead to opposite outcomes. For example, iNOS promotes glioma stem cell proliferation but suppresses proliferation of T cells. Such conflicting actions may help explain why iNOS inhibitors have not yet been beneficial in the clinic. Another possible explanation is that mice often fail to model humans sufficiently to predict the outcome of an experimental intervention. For example, it is far from clear whether humans have the robust capacity to regenerate lung tissues that Seimetz and colleagues observed in mice. Notwithstanding such concerns, the new findings are likely to spur clinical trials of iNOS inhibitors as an experimental treatment for emphysema.
Figure 1. Three Potential Settings for Therapeutically Targeting iNOS
Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO), contributing to the formation of peroxynitrite (OONO À ) (center). Diverse and sometimes opposing functional effects (inner circle) result from a large number of specific molecular modifications, a few of which are illustrated in the outer ring. For instance, in the lungs of mice with emphysema, iNOS increased the level of Bax and matrix metalloproteinase 9 (Mmp9) but decreased the level of tissue inhibitor of matrix metalloproteinase 3 (Timp3). In tumors, iNOS contributed to nitration of CCL2 (C-C chemokine ligand 2, also called monocyte chemotactic protein 1). CDA1 is an abbreviation for cell-cycle inhibitor cell division autoantigen.
